Key facts
- Some patients developed cancer in a late-stage clinical trial for Abivax's bowel-disease drug.
- Abivax stated that the cancer cases were unrelated to the treatment.
- Abivax shares fell following the announcement of these adverse events.
Clinical trials are crucial for determining the safety and efficacy of new drugs. Unexpected adverse events, even if unrelated to the treatment, can impact a drug's development timeline and market perception, leading to significant stock price movements.